According to a recent LinkedIn post from SanegeneBio, the company plans to participate in the OPT Congress Oligonucleotide, mRNA & Peptide Therapeutics event in Boston on March 18–19. The post indicates that Chief Technology Officer and Head of U.S. Operations Dr. Marc Abrams is expected to present updates on SanegeneBio’s LEAD siRNA delivery platforms and development pipeline.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post also notes that Vice President of CMC Development Dr. Sibo Jiang will present a case study on siRNA CMC development, focusing on scalable manufacturing strategies to support IND-enabling work for extrahepatic programs. From an investor perspective, this conference visibility may signal ongoing progress in platform development and manufacturing readiness, which could be relevant for future partnering, financing, and competitive positioning in the oligonucleotide therapeutics space.